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Background: In the present study, an arterial tissue-engineered vascular media (TEVM) was produced from cultured
human smooth muscle cells of the umbilical artery and we took advantage of this model to evaluate the regulation of
contraction and the signalling pathways of polyphenols in arteries.
Methods: Cultured human smooth muscle cells of the umbilical artery were used to produce arterial TEVMs. Contraction
experiments were performed to determine intracellular targets involved in the modulation of contraction by polyphenols
extract from red wine, Provinols (SEPPIC Groupe Air Liquide, Paris, France).
Results: Smooth muscle cells in arterial TEVM displayed a differentiated phenotype as demonstrated by the expression of
-smooth muscle actin, a vascular smooth muscle-specific marker, and tissue contraction in response to vasoconstrictor
and vasodilator agents. Contractions caused by histamine were associated with an increase in [Ca2]i and a Ca2-
independent signalling pathway. The latter pathway involved mechanisms sensitive to protein kinase C, myosin light
chain kinase, and Rho-associated protein kinase inhibitors. The regulation of contraction induced by Provinols shows
that treatment of arterial TEVM with this compound significantly decreased histamine-induced contraction. This effect
was associated with the inhibition of the Rho-associated protein kinase pathway and the decrease in -smooth muscle
actin expression.
Conclusion: The use of arterial TEVM, brings new insights into the mechanisms by which polyphenols regulate vascular
contraction in the human artery. ( J Vasc Surg 2007;46:764-72.)
Clinical Relevance: The clinical relevance of this study relies on the potential of polyphenols in cardiovascular protection.
The available evidence indicates that polyphenols might be of therapeutic benefit in cardiovascular diseases associated
with either endothelial dysfunction or vascular hypereactivity such as hypertension. The ability of polyphenols to decrease
response to vasoconstrictor agonists in arterial human tissue-engineered vascular media partially explain their capacity to
prevent the increase of blood pressure and vascular reactivity in hypertensive animals. These data reinforce clinical studies
showing that polyphenols-rich foods can improve the condition of patients with hypertension, atherosclerosis, and
coronary heart disease. The use of human arterial tissue-engineered vascular media brings new insights into the
mechanisms by which polyphenols regulate arterial contraction. The inhibition of Rho kinase and the decrease in
-smooth muscle actin and myosin light chain kinase expression by Provinols may pinpoint new therapeutic pathways to
discover targets for the treatment of cardiovascular diseases such as hypertension.Natural dietary polyphenolic compounds are present in
a wide variety of plants and are thought to protect against
cardiovascular diseases and cancer.1-3 Polyphenolic com-
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764pounds possess multiple biologic activities, including anti-
oxidant properties and a capacity to inhibit platelet aggre-
gation that could be involved in protecting against
atherosclerosis development as well as vascular thrombosis
and occlusion.
In our previous study, we determined the vascular
effect of red wine polyphenols. Red wine polyphenols pos-
sess a vasorelaxant activity through a mechanism dependent
on the presence of the endothelium and through a direct
effect on smooth muscle cells in rat aortic rings.3 In addi-
tion, it has been shown that the short-term administration
of red wine polyphenolic compounds including Provinols
(SEPPIC Groupe Air Liquide, Paris, France) to rats re-
sulted in a decrease in arterial blood pressure, associated
with an improvement in endothelial function, and an in-
crease in inducible nitric oxide (NO) synthase and cycloox-
ygenase-2 expression in the aortic wall.4
Recently, we have shown that an extraendothelial NO-
pathway was implicated in a subtle alteration of a thapsigargin-
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to calcium2 (Ca2) release from the intracellular store in
rat aortic smooth muscle cells (SMCs).5 However, the
intracellular protein targets of Provinols involved in the
modulation of arterial contraction mechanism have not
been determined yet.
The method for producing tissue-engineered blood
vessels based exclusively on the use of human cells (ie,
without artificial scaffolding) has previously been described
using endothelial cells and SMCs from the human umbilical
vein to reconstitute the endothelium and media, and der-
mal or vascular fibroblasts to form adventitia.6-8 Our group
has recently used this method to construct a tissue-engineered
vascular media (TEVM) from venous SMCs as an alterna-
tive to the use of human vessels to perform pharmacologic
studies. It has been shown that this TEVM produced from
venous SMCs possesses pharmacologic properties resem-
bling those of a native human vein.9-11
Furthermore, we have recently described the intracel-
lular mechanism of contraction in human vein TEVM in
response to vasoconstrictor agonists such as histamine and
bradykinin. Agonist stimulation resulted in an increase in
the intracellular calcium concentration ([Ca2]i) in venous
TEVM, associated with a slight stimulation of the myosin
light chain kinase (MLCK) pathway and activation of the
Ca2 sensitization mechanism.9
We have also used the venous TEVM to study the
effects of polyphenols on venous contraction. Natural di-
etary polyphenols have been used in general to treat vascu-
lar diseases originating from veins.12 Only a few studies
have reported the underlying mechanism involved in the
phlebotropic and venoprotective properties of polyphe-
nolic compounds in human blood vessels. In rat femoral
vein, Savineau and Marthan13 demonstrated the venotonic
action of a flavone derivative, diosmin, probably through its
capacity to decrease Ca2 sensitivity.13 The use of venous
TEVM shed new light in the mechanism involved in the
potentiating effect of Provinols.14
In the present study, we extend the importance of using
arterial TEVM to decipher the mechanisms involved in the
reduced response of arteries to vasoconstrictor agent by
Provinols. This model avoids any interference with either
the endothelium or the adventitia on the effect of Provi-
nols. We took advantage of the potential of the TEVM to
determine the intracellular targets involved in the modula-
tion of contraction of arteries by Provinols using arterial
TEVM produced from human SMCs cultured from arteries.
METHODS
Tissue culture. Human arterial SMCs from the um-
bilical cord of two donors were isolated by the explant
method of Ross as described before.15 Briefly, arteries from
umbilical cords were slit longitudinally and the endothe-
lium was removed by scrubbing with gauze. Strips of the
media were dissected, cut in small sections and kept in as
explants in culture consisting of Dulbecco modified Eagle’s
medium-Ham’s F12 modified medium (3:1), 10% fetal
bovine serum, and antibiotics (100 U/mL penicillin and0.1 mg/mL streptomycin). After 2 weeks of culture, SMCs
from the artery of human umbilical cords migrated from
the explants and proliferated. Two weeks later, the cells
were trypsinized and plated at a density of 104 viable
cells/cm2 in tissue culture flasks.
Arterial TEVM were obtained by a slight modification
of the self-assembly approach in tissue engineering, previ-
ously described.9 Briefly, arterial TEVM were produced by
culturing human arterial SMCs in a medium supplemented
with 50 g/mL of sodium ascorbate to stimulate extracel-
lular matrix synthesis. After 15 to 20 days of culture, the
cells form sheets comprised of cells and extracellular matrix
that could be wrapped around a tubular support (outside
diameter, 4 mm), to produce a cylinder composed of
approximately four concentric sheet layers. After 1 week of
maturation, the concentric sheet layers adhered to one
another, forming a cohesive tubular tissue. The arterial
TEVM were cultured for about 3 weeks, and then the
reconstituted arterial media were used for experiments.
More than 50 arterial TEVM were produced.
Vascular reactivity. The arterial TEVM were cut into
4 mm-long rings. Four rings were obtained from each
arterial TEVM. This allowed us to perform comparative
experiments using the vasoconstrictor agonists in the ab-
sence or in the presence of inhibitors. The rings were then
mounted on a standard organ bath filled with a physiologic
salt solution (PSS; composition in mM: sodium chloride,
119; potassium chloride, 4.7; calcium chloride, 1.25; mag-
nesium sulfate, 1.17; potassium dihydrogen phosphate,
1.18; sodium bicarbonate, 25; glucose, 11). The arterial
TEVM rings were maintained at 37°C and continuously
aerated with a 95% oxygen, 5% carbon dioxide mixture.
The resting tension was adjusted to 0.5 g. The tension was
measured with an isometric force transducer.
After an equilibration period of 90 minutes, the vessels
were maximally contracted with histamine (104 M) to test
their contractile capacity.
Experimental protocol. Concentration response curves
to histamine and bradykinin were constructed in a cumula-
tive manner for arterial TEVM. To study the relaxant
capacity of arterial TEVM, increasing concentrations of a
nitric oxide donor, 3-morpholinosydnonimine (SIN-1),
and an activator of adenylate cyclase, forskolin, were added
to the bath on arterial TEVM that was precontracted with
histamine (100 M). In some experiments, the effect of
Provinols on arterial TEVM was investigated. The arterial
TEVM were treated for 24 hours with Provinols (102
g/L). The Provinols stock solution was dissolved in a
culture medium containing 1% dimethyl sulfoxide (DMSO).
The final concentration of DMSO was less than 0.01%. This
concentration of Provinols has been shown to induce max-
imal endothelium-dependent relaxation of the precon-
tracted rat aorta.3
The intracellular mechanism of contraction and partic-
ularly the Ca2-sensitive pathway and Ca2 protein sensi-
tization were examined. The involvement of phospholipase
A2, Rho-kinase, MLCK, and protein kinase C, pathways in
histamine-induced contraction in arterial TEVM was stud-
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M; Y 27632, 5  107 M; ML-9 [1-(5-chloronaphthalene-
1-sulfonyl)-1H-hexahydro-1,4-diazepine], 10 M; and
GF109203X, 30 M. All the inhibitors were used at their
maximally effective concentrations. In some experiments,
the involvement of oxygen radical (O2
) in the modulation
of contraction induced by Provinols treatment was studied
using an O2
 scavenger, namely manganese (III) tetrakis
(1-methyl-4-pyridyl) porphyrin pentachloride (MnTMPyP,
100 M).
Measurement of [Ca2]. Changes in [Ca2]i were
determined by measuring the fluorescence of trapped
Fura-2 with a dual excitation wavelength fluorometer (Flu-
orolog II, SPEX, Edison, NJ) using the method previously
described.9 Arterial TEVM were loaded with Fura-2 by
incubation in the dark with PSS containing 5 M Fura-2
AM (the acetoxymethyl ester of Fura-2) and 2% pluronic
acid for 2 hours. The increase in [Ca2]i in response to
histamine (104 M) was obtained by the measure of the
ratio of fluorescence (measured at 510 nm) at the two
excitation wavelengths (340/380 nm). These measures
were calculated after subtraction of the autofluorescence at
340 and 380 nm, in control, 24 hours’, and 96 hours’
Provinols-treated arterial TEVM.
Immunoblotting. Arterial TEVM were homoge-
nized in a lysis buffer (50 mM Tris pH 7.5, 250 mM
sodium chloride, 8 mM magnesium chloride, 10 g/mL
leupeptin, 10 g/ml aprotinin and 10 g/ml pepstatin, 1
mM phenylmethylsulfonyl fluoride [PMSF], 5 mM ethyl-
enediaminetetraacetic acid [EDTA], 0.5 mM ethylenegly-
cotetraacetic acid, 2 mM sodium orthovanadate, 1% Triton
X-100).
Then, 30 g of total protein from the supernatant
fractions were loaded onto 10% sodium dodecyl sulfate-
polyacrylamide gels for electrophoresis and then transferred
to a nitrocellulose membrane. After electrophoresis, immu-
nostaining of the contractile proteins -actin, the -actin
promoter activator, serum response factor, Rho A-, B-,
C-isoforms (Rho), Rho-kinase, and MLCK was performed
using specific mouse monoclonal anti--actin, anti-serum
response factor (Santa Cruz Biotechnology, Santa Cruz,
Calif), anti-Rho-kinase I (BD Transduction Laboratories,
San Diego, Calif), anti-MLCK (Sigma, Grenoble, France)
antibodies, and polyclonal rabbit anti-Rho A-, B-, C- iso-
forms (Upstate biotechnologies, Euromedex) antibodies,
and revealed with peroxidase-conjugated goat antimouse
and antirabbit antibodies (Sigma). Antibody-labelled
bands on the blots were detected using an enhanced chemi-
luminescence assay (ECL, Amersham, Buckinghamshire,
UK). The level of protein was measured by densitometry.
Monoclonal mouse anti--actin immunostaining was used
to control the homogeneity of proteins between samples.
Rho activity assay. Arterial TEVM that had been
treated with Provinols (102 g/L) or not, before or after
stimulation with histamine (104 M), were lysed in a lysis
buffer (25 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic
acid, pH 7.5; 150 mM sodium chloride, 1% Igepal CA-
630, 10 mM magnesium chloride, 1 mM EDTA, 2% glyc-erol, 10 g/mL leupeptin, 10 g/mL aprotinin, 1 mM
sodium orthovanadate) containing 25 mM sodium fluo-
ride. Cell lysates were clarified by centrifugation at 14,000g
at 4°C for 10 minutes, and 500 L of lysate were incubated
in the presence of the Rhotekin Rho binding domain (30
g) at 4°C for 45 minutes.
The beads were microcentrifuged for 5 seconds at
14,000g and the supernatant was removed. The beads were
washed three times with a washing buffer (50 mM Tris, pH
7.5, 1% Triton X-100, 150 mM sodium chloride, 10 mM
magnesium chloride, 10 g/mL leupeptin, 10 g/mL
aprotinin, and 0.1 mM PMSF). Bound Rho proteins were
detected by Western blotting using a rabbit polyclonal
antibody against Rho A-, B-, and C- isoforms.
Expression of results and statistical analysis. Con-
tractions were expressed as a percentage of the maximal
contractile response obtained with 104 M histamine. The
maximal responses obtained were 190  22 mg (n  20)
with histamine and 183 21 mg (n 18) with bradykinin.
The changes in [Ca2]i were expressed as the ratio of
fluorescence values. Western blot results were evaluated by
densitometric analysis and expressed as a percentage of the
control value. MLCK activity was expressed as pmol P/mg
total protein/min. Results are the means  SEM, and the
Student unpaired t test or analysis of variance was used for
statistical analysis, as indicated in the figure legends. P 	
.05 was considered significant. For Figures 2 and 3, we have
used two-way analysis of variance for the statistics, which
takes into account all points of the curves including the
slope and maximal responses.
Drugs. The Provinols dry powder was provided by D.
Ageron (Société Française de Distilleries, Vallont Pont
d’Arc, France). The Provinols polyphenol content is in
mg/g of dry powder: hydroxycinnamic acid 18, catechins
38, flavonols 14, anthocyanins 61, proanthocyanidols 480.
Ascorbic acid, histamine, bradykinin, quinacrine, fura-2,
SIN-1, and forskolin were purchased from Sigma. ML-9
and Y 27632 were purchased from Calbiochem (Paris,
France). GF109203X was obtained from Tocris (Illkirch,
France). MnTMPyP was purchased from the Alexis Corpo-
ration (Coger, France). GF109203X was obtained from
Tocris (Illkirch, France).
RESULTS
Both bradykinin and histamine produced concentration-
dependent contraction in arterial TEVM (arterial TEVM)
(Fig 1, A and B, respectively). As expected, the nitric oxide
donor, SIN-1, and the adenylyl cyclase activator, forskolin,
induced a concentration-dependent vascular relaxation (Fig 1,
C and D, respectively).
The involvement of the MLCK, Rho-kinase, and
protein kinase C pathways in the histamine-induced
contraction of arterial TEVM was determined using Y
27632, 5.0 107 M; and GF109203X, 30 M (Fig 2).
The presence of these inhibitors significantly reduced
histamine-induced contraction in arterial TEVM (Fig 2,
A; P 	 .001; 2B, P 	 .05; and 2C, P 	 .05, respectively)
10 ar
ulfon
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shown).
The effect of a 24 hour treatment with Provinols on
histamine-induced contraction is represented in Fig 3. Re-
sults showed that Provinols treatment significantly reduced
histamine-induced contraction compared with control ar-
terial TEVM (P 	 .001; Fig 3, A). Furthermore, Provinols
treatment decreased the contractile response to bradykinin
(maximal contraction being 183  5 mg, n  18 for
control and 135  6 mg, n  15 for Provinols-treated
arterial TEVM, P 	 .05).
The stimulation of arterial TEVM with histamine used
at its maximally active concentration (104 M) produced
an increase in [Ca2]i in arterial TEVM (Fig 3, B). How-
ever, this increase in [Ca2]i was not significantly affected
Fig 1. Concentration-response curves for (A) bradykin
tissue-engineered vascular media (TEVM) rings. Conce
(SIN-1) and (D) forskolin-induced relaxation of arteria
M). Values are means  standard error of the mean of
Fig 2. Concentration-response curves of histamine-ind
(TEVM) rings in the presence of (A) the myosin light
inhibitor, Y 27632 (0.5 M), and (C) the protein kina
standard error of the mean of five to six arterial TEVM
analysis of variance. ML-9, [1-(5-chloronaphthalene-1-sby Provinols treatment.The O2
 scavenger MnTMPyP (100 M) was added
to the culture medium for 24 hours for control and for
Provinols-treated arterial TEVM. MnTMPyP did not affect
the contraction induced by histamine in control arterial
TEVM. However, the presence of MnTMPyP abolished
Provinols-induced hyporeactivity in response to histamine
in arterial TEVM (Fig 3, C).
The involvement of the phospholipase A2 and Rho-
kinase pathways in histamine-induced contraction in
Provinols-treated arterial TEVM was determined using the
selective inhibitors quinacrine (10 M) and Y 27632 (5 
107 M; Fig 4). At these concentrations, both Y 27632 and
quinacrine, alone and in combination, significantly inhib-
ited the contraction induced by histamine at its maximally
active concentration (104 M). However, Provinols treat-
uced and (B) histamine-induced contraction of arterial
ion-response curves for (C) 3-morpholinosydnonimine
M rings that were precontracted with histamine (100
terial TEVM experiments.
contraction in arterial tissue-engineered vascular media
kinase inhibitor, ML-9 (10 M), (B) the Rho-kinase
inhibitor, GF109203X (30 M). Values are means 
iments. *P 	 .5 and *** P 	 .001 vs control by use of
yl)-1H-hexahydro-1,4-diazepine.in-ind
ntrat
l TEVuced
chain
se C
experment of arterial TEVM decreased the inhibitory effect of Y
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tion (P 	 .01, Fig 4).
Western blot analysis showed that Rho-kinase expres-
sion was not altered by Provinols treatment compared with
control arterial TEVM (Fig 4, B). Rho activity and expres-
sion were studied in arterial TEVM cultured for 24 hours
without (control) and with Provinols (Fig 4, C and D). The
basal Rho activity was not significantly different between
Fig 3. A, Concentration-response curves show histami
media (TEVM) rings cultured 24 hours without (contro
error of the mean (SEM) of five to six arterial TEVM ex
arterial TEVM rings incubated 24 hours in the absence (
means  SEM of three arterial TEVM experiments.
contraction in arterial TEVM rings incubated for 24
(1-methyl-4-pyridyl) porphyrin pentachloride (MnTMP
g/L). Values are means  SEM of five to six arterial TEV
variance.
Fig 4. A, Histogram shows the percentage of inhibiti
Rho-kinase inhibitor, Y 27632 (0.5 M), the phospholi
arterial tissue-engineered vascular media (TEVM) rings
(PRO; 102 g/L). Values are means standard error of
vs control by use of unpaired t test. B, Western blot sh
cultured 24 hours without (control) or with Provinols (
experiments. C and D, Western blot, with anti-Rho-kina
(C) activity of Rho and (D) the expression of Rho protei
in arterial TEVM rings cultured 24 hours without (contr
three arterial TEVM experiments.both groups. The stimulation of arterial TEVM with hista-mine did not induce any increase in Rho activity, neither in
the control, nor in the Provinols-treated group (Fig 4,  C).
Rho was expressed both in control and Provinols-treated
groups. Provinols treatment did not alter the expression of
the Rho protein (Fig 4, D).
The involvement of the MLCK signalling pathway in
Provinols-treated arterial TEVM is represented in Fig 5.
The inhibition of MLCK by ML-9 (10 M) significantly
duced contraction in arterial tissue-engineered vascular
ith Provinols (102 g/L). Values are means standard
ents. B, Histogram shows the measure of Ca2 ratio in
ol) or the presence of Provinols (102 g/L). Values are
oncentration-response curves show histamine-induced
in the presence of 100 M manganese (III) tetrakis
without (control) or with Provinols treatment (102
xperiments. ***P 	 .001 vs control by use of analysis of
histamine-induced contraction in the presence of the
2 inhibitor, quinacrine (10 M), or both inhibitors, in
red 24 hours without (control, CTR) or with Provinols
ean of five to six arterial TEVM experiments. **P	 .01
g the expression of Rho-kinase in arterial TEVM rings
g/L). Values are representative of three arterial TEVM
d anti-Rho A-, B-, C- isoforms antibodies, showing the
er basal and stimulated (histamine, 104 M) conditions
with Provinols (102 g/L). Values are representative ofne-in
l) or w
perim
contr
C, C
hours
yP),
M eon of
pase A
cultu
the m
owin
102
se an
n und
ol) ordecreased histamine-induced contraction in control ar-
ols (
JOURNAL OF VASCULAR SURGERY
Volume 46, Number 4 Diebolt et al 769terial TEVM. Provinols-treatment did not significantly
modify the inhibitory effect of ML-9 (Fig 5 A). Interest-
ingly, Western blot analysis showed that MLCK expres-
sion was significantly decreased in Provinols-treated ar-
terial TEVM as compared to the control (P 	 .01) (Fig
5,  B).
Expression of -actin was studied in control and
Provinols-treated arterial TEVM (Fig 6,  A). Provinols
treatment produced a significant decrease in the expres-
sion of -actin in arterial TEVM compared with the
control. However, the expression of the transcription
Fig 5. Histogram shows the percentage of inhibition of
light chain kinase (MLCK) inhibitor, ML-9 (10 M
diazepine]), in arterial tissue-engineered vascular media
Provinols (102 g/L). Values are means standard erro
and optical density measurement of the MLCK expressi
(control) or with Provinols (102 g/L). Values are mea
**P 	 .01 vs control by use of unpaired t test.
Fig 6. A, Western blot and optical density measureme
tissue-engineered vascular media (TEVM) rings culture
Values are mean  standard error of the mean of blottin
by use of unpaired t test. B, Western blot showing the exp
rings cultured 24 hours without (control) or with Provinfactor of -actin, serum response factor, was not alteredin the Provinols-treated group compared with the con-
trol (Fig 6,  B).
DISCUSSION
This study describes the modulation of contraction
produced by a red wine polyphenolic extract, Provinols,
evaluated using a human model of arteries produced
by tissue engineering. Provinols treatment of arterial
TEVM decreased histamine-induced contraction. This
effect was associated with the inhibition of the Rho-
mine-induced contraction in the presence of the myosin
-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-
M) rings cultured 24 hours without (control) or with
e mean (SEM) of 5 to 6 arterial TEVM. B, Western blot
nds of arterial TEVM rings cultured 24 hours without
SEM of blotting from five arterial TEVM experiments.
the -smooth muscle actin expression bands in arterial
hours without (control) or with Provinols (102 g/L).
five arterial TEVM experiments. **P 	 .01 vs control
on of serum response factor (SRF) in four arterial TEVM
102 g/L).hista
; [1
(TEV
r of th
on ba
ns nt of
d 24
g from
ressikinase pathway and a decrease in -smooth muscle actin
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explain the regulation of contraction by polyphenols in
the human artery.
Previous studies have shown that vascular media recon-
stituted from human SMCs from the umbilical vein express
functional histamine H1, bradykinin B2 purinergic P2, and
endothelin receptors, and produce cyclic nucleotides to
induce vascular relaxation.9,10 In the present study, we
provide evidence that these pathways were also functional
in arterial TEVM.
Vascular contraction involves both an elevation in
[Ca2]i, resulting in an increase in MLCK activity and a
Ca2-independent signalling pathway through an en-
hancement of the sensitivity of the contractile protein by
different kinases such as Rho-kinase, protein kinase C, or
tyrosine kinase.16 In the present study, the histamine-
induced contraction was associated with an increase in
[Ca2]i. This histamine-induced contraction was inhibited
in the presence of the MLCK, Rho-kinase, and protein
kinase C inhibitors, ML-9, Y 27632, and GF109203X,
respectively, suggesting that these proteins were involved in
the signal transduction leading to human arterial TEVM
contraction. These results are consistent with those re-
ported by others in previous studies performed with native
vessels.16-18 Furthermore, we have previously reported in
human small omental arteries that protein kinase C and
Rho-kinase are involved in the contraction mechanism.19
Several studies performed in animal models have sug-
gested a beneficial effect of Provinols on the cardiovascular
system. Indeed, it has been reported that Provinols pro-
duced endothelium-dependent relaxation in rat aortic
rings, by a mechanism that involved an enhancement of
nitric oxide synthesis.3,20 We also reported that short-term
oral administration of Provinols produced a decrease in
blood pressure in rats, which was associated with an en-
hanced endothelium-dependent relaxation and an induc-
tion of gene expression (of inducible nitric oxide synthase
and cyclooxygenase-2) within the arterial wall.4 Further-
more, we reported that the decrease in blood pressure and
the improvement of cardiovascular structure and function
obtained in hypertensive rats by Provinols treatment were
associated with an increased nitric oxide synthase activity.21
With regard to the effect of polyphenols in the regula-
tion of vascular contraction of arterial TEVM, we have
demonstrated that Provinols treatment in rats resulted in a
modulation of Ca2 handling in the aorta by a mechanism
dependent on the nitric oxide pathway.5 Recently, we have
shown in human venous TEVM that Provinols was able to
enhance contractile responses induced by histamine and
bradykinin. This effect of Provinols took place at the level of
phospholipase A2–Rho-kinase pathway and was associated
with an enhancement of myosin light chain kinase activity
in this venous model.14 In the present study, we took
advantage of the human arterial TEVM to evaluate the
pharmacologic mechanisms involved in the regulation of
arterial vascular SMC contractile proteins after Provinols
treatment.Provinols significantly reduced vascular reactivity in
contraction in arterial TEVM induced by histamine and
bradykinin. However, the histamine-induced increase in
[Ca2] was unchanged in Provinols-treated arterial TEVM
compared with the control. These data suggest that Provi-
nols induced an arterial hyporeactivity by a Ca2-independent
mechanism.
Hyporeactivity induced by Provinols was prevented in
the presence of the O2
 scavenger MnTMPyP. These data
suggests that an O2
-sensitive mechanism might be in-
volved in the effect of Provinols. It has recently been shown
that O2
 attenuated smooth muscle contraction by mod-
ulating Ca2 handling in bovine aortic smooth muscle
cells.22 Thus, one can advance the hypothesis that Provi-
nols might increase the activity of oxygenases, such as
nicotinamide adenine dinucleotide phosphate hydrogen
oxidase or xanthine oxidase, or decrease the activity of
superoxide dismutase. In a previous study, we have shown
the implication of an O2
-sensitive mechanism in the
Provinols-induced increase in [Ca2]i and activation of
nitric oxide synthase in endothelial cells.23 Furthermore, it
has recently been shown that Provinols treatment improved
endothelium-dependent vascular relaxation in the rat aorta
by a mechanism dependent on O2
 production.4 We ex-
tend our understanding of the involvement of O2
 in the
regulation of contraction by Provinols in the present study.
The presence of an inhibitor of Rho-kinase, Y 27632,
significantly decreased histamine-induced contraction in
control but not in Provinols-treated arterial TEVM. How-
ever, the expression of Rho-kinase was not significantly
different between both groups. These results suggest that
Provinols treatment in human arterial TEVM could induce
an inhibition of the Rho-kinase pathway. Rho-kinase has
been shown to play an essential role in multiple cellular
events, including SMC contraction and cytoskeletal con-
traction, cellular adhesion and motility.24 Furthermore, the
abnormal activity of Rho-kinase has been shown to be
involved in experimental hypertension,25,26 atherosclerosis,27
restenosis,28 and coronary spasm.29
Rho-kinase has been reported to be activated by two
pathways, Rho protein30 and arachidonic acid31 released by
phospholipase A2 or D. Rho activity in histamine-stimulated
arterial TEVM was not significantly different between con-
trol and Provinols-treated arterial TEVM. However, we
have shown that quinacrine, a phospholipase A2 inhibitor,
inhibited histamine-induced contraction in control arterial
TEVM, but not in the Provinols-treated group. Taken
together, one can advance the hypothesis that Provinols
induced vascular hyporeactivity through Rho-kinase signal-
ling pathway and a mechanism sensitive to phospholipase
A2-inhibitor in arterial TEVM.
In human arterial TEVM, Provinols treatment reduced
the contraction induced by histamine, and this effect was
associated with a decrease in -actin and is regulated by the
transcription factor serum response factor, an activator of
the -actin promoter. However, Provinols treatment did
not alter serum response factor expression in the present
study, suggesting that Provinols treatment decreased -ac-
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between the decrease in -smooth muscle actin content
and reduced vascular contractility by Provinols-treatment
cannot be excluded. Further investigation is needed to
determine the mechanisms involved in the effect of Provi-
nols.
When compared with our previous report with venous
TEVM, the contraction and relaxation in response to phar-
macologic agents are similar between arterial TEVM and
venous TEVM. Furthermore, the contractile response to
agonists either in venous TEVM9,14 or arterial TEVM (this
article) involve an increase of intracellular Ca2 and a
Ca2-independent signalling pathway through an en-
hancement of the sensitivity of the contractile protein by
different kinases such as Rho-kinase. The only divergent
response that we have observed so far is the effect of
Provinols, in which a potentiating effect was seen in venous
TEVM, whereas an inhibitory effect was reported in arte-
rial TEVM on vascular contractility. With regard to venous
TEVM, natural dietary polyphenols have been used in
general to treat vascular diseases originating from veins.12
Only a few studies have reported the underlying mech-
anism involved in the phlebotropic and venoprotective
properties of polyphenolic compounds in human blood
vessels. In rat femoral vein, Savineau and Marthan13 dem-
onstrated the venotonic action of a flavone derivative,
diosmin, probably through its capacity in increasing Ca2
sensitivity.13 The use of venous TEVM shed new light in
the mechanism involved in the potentiating effect of Provi-
nols.14
In the present study, we extend the importance of using
arterial TEVM to decipher the mechanisms involved in the
reduced response to vasoconstrictor agent by Provinols.
This model avoids any interference with either the endo-
thelium or the adventitia on the effect of Provinols. The
present study reinforce data obtained in rat aorta denuded
of the endothelium in which red wine polyphenol com-
pounds, including Provinols, also produced vascular hypo-
reactivity in arterial blood vessels.4,5 Although, we do not
know the reason of the differential effect of Provinols
between vein and artery, the present study highlights the
importance of the use of arterial TEVM to better under-
standing the intracellular mechanisms implicated. These
results are consistent with previous results obtained with
venous TEVM indicating that subtile differences such as
receptor expression are preserved in the reconstituted tis-
sue. We have shown that the endothelin response profile of
venous TEVM was similar to that of the blood vessel from
which the VSMCs were isolated and cultured.10,11
CONCLUSION
The use of human arterial TEVM, brings new insights
into the mechanisms by which polyphenols regulate arterial
contraction. The inhibition of Rho-kinase and the decrease
in -SMA and MLCK expression by Provinols may pin-
point new therapeutic pathways to discover targets for the
treatment of cardiovascular diseases such as hypertension.We thank Cindy Hayward for the critical reading of the
manuscript. We thank Mireille Gaire for her technical assis-
tance with the MLCK activity assay.
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